Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study).

CONCLUSION: Fulvestrant 500 mg is an effective and safe treatment for patients with advanced or recurrent breast cancer after prior endocrine treatment. PMID: 31292328 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31292328?dopt=Abstract

Source: Journal of Nippon Medical School - July 13, 2019 Category: Universities & Medical Training Authors: Kimizuka K, Inoue K, E Nagai S, Saito T, Nakano S, Futsuhara K, Yamada H, Kaneko S, Sakurai T, Hata S, Kurosumi M Tags: J Nippon Med Sch Source Type: research